Login / Signup

A double-blind, placebo-controlled, single-ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM15136, a novel long-acting glucagon analogue, in healthy subjects.

Ki Young HuhJun Gi HwangWonjung ShinSeungJae BaekJaeDuk ChoiNora LeeYoung Min ChoHoward Lee
Published in: Diabetes, obesity & metabolism (2021)
A single subcutaneous dose of HM15136 at 10-120 μg/kg was safe and well tolerated. The long half-life of HM15136, coupled with an increase in blood glucose for ~2 weeks, may warrant a weekly dosing regimen.
Keyphrases
  • blood glucose
  • placebo controlled
  • double blind
  • glycemic control
  • open label
  • blood pressure
  • study protocol
  • type diabetes
  • phase ii
  • insulin resistance
  • rectal cancer
  • locally advanced